IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1 (currently amended). A compound ~~of general formula I~~, **a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I**:



Formula I

[[where]] wherein:

~~R_1 is selected from the group formed by H, --$(CH_2)_3$--, --$(CH_2)_4$--, --CH_2--S--CH_2, --S--CH_2--CH_2--;~~

R_2 is selected from the group ~~formed by~~ **consisting of** N, **NH and** S; **wherein**

if R_2 is N, then R_1 is selected from the group consisting of -$(CH_2)_3$-, -$(CH_2)_4$-, -CH_2SCH_2, and -SCH_2CH_2-;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of **[[0]] zero** or 1;

Z is selected from the group ~~formed by~~ **consisting of** ~~C2-C10-alkyl~~ **C_2-C_{10}-alkyl**, ~~C2-C10-alkenyl~~ **C_2-C_{10}-alkenyl**, **and** ~~C2-C10-alkinyl~~ **C_2-C_{10}-alkynyl**;

R_3 is selected from the group ~~formed by~~ **consisting of** H, ~~C1-C10-alkyl~~ **C_1-C_{10}-alkyl**, aryl, **and** aralkyl;

m has a value of **[[0]] zero, [[to]] 1, or** 2;

R_4 is selected from the group ~~formed by~~ **consisting of** O[[,]] **and** CH_2;

R_5 is selected from the group ~~**formed by:**~~ **consisting of**







[[where]] **wherein**:

R_6 is selected from the group ~~formed by~~ **consisting of** H, ~~C1-C5-alkyl~~ **C_1-C_5-alkyl**, ~~C1-C5-alkoxyl~~ **C_1-C_5-alkoxyl**, OH, F, Cl, Br, **and** I;

X is selected from the group ~~formed by~~ **consisting of** O, S, NH, **and** NCH_3;

Y is selected from the group ~~formed by~~ **consisting of** O[[,]] **and** NH;

W is selected from the group ~~formed by~~ **consisting of** S[[,]] **and** NH[[;]]

~~and their salts and solvates~~.

2 (currently amended). **[[A]]** **The** compound**, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer** according to claim 1, ~~characterized in that~~ **wherein:**

Z ~~represents~~ **is** ~~a C2-C10-alkyl~~ **C_2-C_{10}-alkyl;** **[[group]]** and

R_5 is selected from the group ~~formed by:~~ **consisting of**







[[where]] **wherein**:

R_6 is selected from the group ~~**formed by:**~~ **consisting of** H, ~~**C1-C5-alkyl**~~ **C_1-C_5-alkyl**, ~~**C1-C5-alkoxyl**~~ **C_1-C_5-alkoxyl**, OH, F, Cl, Br, **and** I.

3 (currently amended). **[[A]]** **The** compound**, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer** according to claim 1, ~~**characterized in that**~~ **wherein:**

Z is butyl**[[,]]**;

R_3 is H; and

R_5 is selected from the group ~~**formed by:**~~ **consisting of**



and ;

[[where]] wherein:

R_6 is selected from the group ~~formed by~~ consisting of H, ~~C1-C5-alkyl~~ C_1-C_5-alkyl, ~~C1-C5-alkoxyl~~ C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

4 (currently amended). A process to prepare a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, ~~according to claim 1 characterized in that:~~ wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of -$(CH_2)_3$-, -$(CH_2)_4$-, -CH_2SCH_2, and -SCH_2CH_2-;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of



, and

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH; and

W is selected from the group consisting of S and NH

comprising:

[[(A)]] **reacting** ~~**the intermediate halogen derivatives II are made to react**~~ **compounds according to Formula II**~~**, where L means Cl, Br,**~~ with **compounds according to Formula** ~~**amines**~~ III ~~**in acetonitrile,**~~ according to [[**the**]] scheme ~~**of reaction**~~ I:



Scheme I



Scheme I

or

[[(B)]] **reacting the compounds of Formula** ~~**the intermediate amines**~~ IV ~~**are made to react**~~ with **the compounds of Formula** ~~**suitable halogen derivatives**~~ V~~**, where L means Cl, Br, in acetonitrile,**~~ according to [[**the**]] scheme ~~**of reaction**~~ II:



Scheme II



Scheme II

[[where]] wherein:

L is selected from the group consisting of Cl and Br; and

the definitions of R_1, R_2, n, Z, m, R_4 and R_5 ~~**in these schemes**~~ are identical to those ~~**previously made for the products of the invention**~~ **in Formula I**.

5 (currently amended). A process according to claim 4, ~~**characterized in that those**~~ **wherein** compounds with R_3 ~~**different from H**~~ **selected from the group consisting of C_1-C_{10}-alkyl, aryl and aralkyl** are obtained by alkylation of the analogues wherein R_3 is hydrogen.

6 (currently amended). A pharmaceutical composition ~~**characterized in that it comprises**~~ **comprising** a therapeutically effective quantity of ~~**any of the compounds**~~ **a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically**

acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I ~~defined in claim 1,~~



Formula I ;

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$, $-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH;

~~together with a~~ **and one or more** pharmaceutically acceptable carrier**s** or excipient**s**.

7 (currently amended). ~~The use of a compound according to claim 1, for the production of a medicine~~ **The method according to claim 19** for the treatment and/or prevention of **a** pathological ~~states~~ **state** wherein **[[the]] a** 5-HT_{1A} receptor ~~agonists are~~ **agonist is** indicated.

8 (currently amended). ~~The use of a compound according to claim 1, for the production of a medicine~~ **The method according to claim 21 wherein the neuroprotection provided comprises [[for]]** the treatment and/or prophylaxis of cerebral damage produced by thromboembolic stroke or cranium-brain traumatic injuries.

9. (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of

(±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;

(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;

(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;

(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;

2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;

2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and

2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

10 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 selected from the group consisting of

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;

2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

11 (new). The process of claim 4, wherein:

Z is C_2-C_{10}-alkyl; and

R_5 is selected from the group consisting of





, and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

12 (new). The process of claim 4, wherein:

Z is butyl;

R_3 is H; and

R_5 is selected from the group consisting of



and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

13 (new). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of:

(±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;

(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;

(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;

(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;

(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;

2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;

2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;

2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;

2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and

2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

14 (new). The process of claim 4, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of

2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;

3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;

3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;

3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;

2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and

3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

15 (new). The pharmaceutical composition of claim 6, wherein:

Z is C_2-C_{10}-alkyl; and

R_5 is selected from the group consisting of





;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

16 (new). The pharmaceutical composition of claim 6, wherein:

Z is butyl;

R_3 is H; and

R_5 is selected from the group consisting of



;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I.

17 (new). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of (±)2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazol;
(±)-2-[4-[(Chroman-2-yl)methylamine]butyl]-1,3-dioxoperhydroimidazo[1,5-c]-thiazol;
(±)-3-[4-[(Chroman-2-yl)methylamine]butyl]-2,4-dioxothiazolidin;
(±)-3-[5-[(Chroman-2-yl)methylamine]pentyl]-2,4-dioxothiazolidin;
(±)-3-[6-[(Chroman-2-yl)methylamine]hexyl]-2,4-dioxothiazolidin;
2-[4-[(Naphth-1-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(Naphth-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Naphth-1-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-yl)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-2-yl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(Phenoxy)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Phenoxy)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
3-[4-[2-(Naphth-1-oxi)ethylamine]butyl]-2,4-dioxothiazolidin;
2-[4-[(Benzimidazol-2-yl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[(o-Methoxyphenyl)methylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[2-(o-Methoxyphenyl)ethylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]-imidazol;
2-[4-[3-(o-Methoxyphenyl)propylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol;
2-[4-[4-(o-Methoxyphenyl)butylamine]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol; and

2-[3-[3-(o-Methoxyphenyl)propylamine]propyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazol.

18 (new). The pharmaceutical composition of claim 6, wherein the compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to Formula I is selected from the group consisting of
2-[4-[(chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole;
3-[4-[(chroman-2-yl)methylamino]butyl]-2,4-dioxothiazolidine;
3-[5-[(chroman-2-yl)methylamino]pentyl]-2,4-dioxothiazolidine;
3-[6-[(chroman-2-yl)methylamino]hexyl]-2,4-dioxothiazolidine;
2-[4-[2-(phenoxy)ethylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-*c*]imidazole; and
3-[4-[2-(phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine.

19 (new). A method for the treatment and/or prevention of a pathological state in a subject in need of such treatment and/or prevention, wherein the method comprises administering to the subject a compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



;

Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

20 (new). The method according to claim 7, wherein the pathological state is selected from the group consisting of anxiety disorders, depression and mixed disorders of anxiety and depression.

21 (new). A method to provide neuroprotection to a subject in need thereof comprising administering to the subject a neuroprotective amount of a compound, a stereochemical isomer of the compound, or solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



Formula I

wherein:

R_2 is selected from the group consisting of N, NH and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S or NH, then R_1 is absent;

if R_2 is NH, then n is 1;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.

22 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ib:



Formula Ib

wherein the definition of n, Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

23 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Ic:



;

Formula Ic

wherein the definition of Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

24 (new). The compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer according to claim 1 wherein the compound corresponds in structure to Formula Id:



;

Formula Id

wherein the definition of R_1, n, Z, R_3, m, R_4 and R_5 are identical to those in claim 1.

25 (new). A compound, a stereochemical isomer of the compound, or a solvate or pharmaceutically acceptable salt of the compound or isomer, wherein the compound corresponds in structure to Formula I:



;

Formula I

wherein:

R_2 is selected from the group consisting of N and S; wherein

if R_2 is N, then R_1 is selected from the group consisting of $-(CH_2)_3-$,$-(CH_2)_4-$, $-CH_2SCH_2$, and $-SCH_2CH_2-$;

if R_2 is S, then R_1 is absent;

n has a value of zero or 1;

Z is selected from the group consisting of C_2-C_{10}-alkyl, C_2-C_{10}-alkenyl, and C_2-C_{10}-alkynyl;

R_3 is selected from the group consisting of H, C_1-C_{10}-alkyl, aryl, and aralkyl;

m has a value of zero, 1, or 2;

R_4 is selected from the group consisting of O and CH_2;

R_5 is selected from the group consisting of





, and ;

wherein:

R_6 is selected from the group consisting of H, C_1-C_5-alkyl, C_1-C_5-alkoxyl, OH, F, Cl, Br, and I;

X is selected from the group consisting of O, S, NH, and NCH_3;

Y is selected from the group consisting of O and NH;

W is selected from the group consisting of S and NH.